|
OptiBiotix Health PLC on Monday said it continues to grow its top line and improve margins, as investments open up a multi territory revenue stream. The York, England-based life sciences firm said revenue surged to £557,000 in the first half of 2025, from £276,000 a year ago. Gross profit jumped to £303,000 from £111,000. The company said it had a growing list of customers, with 30 new clients in Asia in 2025, and a 38% rise in e-commerce customers, which rose to 5,095 in the first half of 2025 from 3,702 a year ago. ‘Our investments in sales and marketing are starting to deliver a multi-channel, multi territory revenue stream, reducing reliance on a single partner or territory,’ commented Chief Executive Officer Stephen O’Hara. ‘Regulatory approvals and health claims have now been approved in all major territories and a network of global manufacturing and distribution partners established. This gives the company a broad base on which to deliver future revenue growth. As the impact of the company reducing costs takes full effect, it continues to grow its top line and improve margins with the aim of achieving profitability across all parts of the business and the group generating positive cashflow.’ In June, the firm noted the publication of a new peer-reviewed study on SlimBiome in the European Journal of Nutrition. The study found that a three-gram dose of SlimBiome significantly reduced insulin levels, hunger and the desire to eat whilst increasing the feeling of fullness, according to OptiBiotix. CEO O’Hara said back in June: ‘We are really pleased to see this study published in such a well-respected journal. He suggested that SlimBiome could be an alternative to competing ’anti-obesity drugs‘ which ’may not be the best choice...for overweight individuals.‘ OptiBiotix Health shares were up 0.9% at 11.60 pence each on Monday morning in London. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
